Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD

Sponsor
Unity Health Toronto
Study ID
NCT06386003
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Psilocybin — DRUG
    Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days.

Study Details

This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD).

Key Dates

First listed
Apr 26, 2024
Start date
Jun 30, 2026
Status verified
Dec 2025
Primary completion
Jan 31, 2027
Completion
Jan 31, 2027

Study Design

Enrollment
15 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental
    Single dose of psilocybin 25mg + Massed cognitive processing therapy

Primary Outcome Measure

Feasibility and tolerability [ Time Frame: Up to 16 weeks ]

Central Contacts

Find similar trials

Nationwide
PTSD (post-traumatic stress disorder) trialsPsychiatry trialsMental health trialsBehavioral health trials

Related Studies